A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer
Robert W Holloway, Premal Thaker, Alberto A Mendivil, Sarfraz Ahmad, Ahmed N Al-Niaimi, James Barter, Tiffany Beck, Setsuko K Chambers, Robert L Coleman, Sarah M Crafton, Erin Crane, Ramez Eskander, Sharad Ghamande, Whitney Graybill, Thomas Herzog, Megan Dr Indermaur, Veena S John, Lisa Landrum, Peter C Lim, Joseph A Lucci, Michael McHale, Bradley J Monk, Kathleen Nadine Moore, Robert Morris, David M O’Malley, Thomas J Reid, Debra Richardson, Peter G Rose, Jennifer M Scalici, Dan-Arin Silasi, Krishnansu Tewari, Edward W Wang
International Journal of Gynecologic Cancer Sep 2023, 33 (9) 1458-1463; DOI: 10.1136/ijgc-2023-004812
